Trial · NCT02620865
Results by group17
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 17 of 17
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Median Overall Survival (OS) | Treatment (Anti-CD3 x Anti-EGFR BATs) | 0.934 | 90% Confidence Interval 0.934 to NA | years | |
| Incidence of Toxicity (CTCAE Version 4.0) | Treatment (Anti-CD3 x Anti-EGFR BATs) | Anorexia | 1 | Participants | |
| Incidence of Toxicity (CTCAE Version 4.0) | Treatment (Anti-CD3 x Anti-EGFR BATs) | Anxiety | 1 | Participants | |
| Incidence of Toxicity (CTCAE Version 4.0) | Treatment (Anti-CD3 x Anti-EGFR BATs) | Chills | 2 | Participants | |
| Incidence of Toxicity (CTCAE Version 4.0) | Treatment (Anti-CD3 x Anti-EGFR BATs) | Depression | 1 | Participants | |
| Incidence of Toxicity (CTCAE Version 4.0) | Treatment (Anti-CD3 x Anti-EGFR BATs) | Diarrhea | 2 | Participants | |
| Incidence of Toxicity (CTCAE Version 4.0) | Treatment (Anti-CD3 x Anti-EGFR BATs) | Dizziness | 1 | Participants | |
| Incidence of Toxicity (CTCAE Version 4.0) | Treatment (Anti-CD3 x Anti-EGFR BATs) | Dry Mouth | 1 | Participants | |
| Incidence of Toxicity (CTCAE Version 4.0) | Treatment (Anti-CD3 x Anti-EGFR BATs) | Fatigue | 2 | Participants | |
| Incidence of Toxicity (CTCAE Version 4.0) | Treatment (Anti-CD3 x Anti-EGFR BATs) | Fever | 2 | Participants | |
| Incidence of Toxicity (CTCAE Version 4.0) | Treatment (Anti-CD3 x Anti-EGFR BATs) | Gastroesophageal reflux disease | 1 | Participants | |
| Incidence of Toxicity (CTCAE Version 4.0) | Treatment (Anti-CD3 x Anti-EGFR BATs) | Headache | 2 | Participants | |
| Incidence of Toxicity (CTCAE Version 4.0) | Treatment (Anti-CD3 x Anti-EGFR BATs) | Myalgia | 1 | Participants | |
| Incidence of Toxicity (CTCAE Version 4.0) | Treatment (Anti-CD3 x Anti-EGFR BATs) | Nausea | 2 | Participants | |
| Incidence of Toxicity (CTCAE Version 4.0) | Treatment (Anti-CD3 x Anti-EGFR BATs) | Rash maculo-papular | 2 | Participants | |
| Incidence of Toxicity (CTCAE Version 4.0) | Treatment (Anti-CD3 x Anti-EGFR BATs) | Vomiting | 1 | Participants | |
| Progression Free Survival (PFS) | Treatment (Anti-CD3 x Anti-EGFR BATs) | 0.934 | 90% Confidence Interval 0.934 to NA | Years |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02620865/results